The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, ...

accounts for 1.7% of all cancer-related deaths. Neuroendocrine carcinoma of the gallbladder (GB-NEC) is a rare subtype of GBC that is more malignant than GBC. Small-cell neuroendocrine carcinoma of ...

Positive Phase 2 data for Paltusotine in carcinoid syndrome and Atumelnant ... glucagon) and tumor growth suppression in neuroendocrine tumors (NETs). As I noted before: In acromegaly, currently ...

In an interview with Targeted Oncology, Chan, who is clinical director at the Gastrointestinal Cancer Center and director for the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer ...

Woese Institute for Genomic Biology, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States Pancreatic neuroendocrine tumors (PNETs) are rare tumors that are often diagnosed ...

The gut microbiome has emerged as a potential factor in cancer pathogenesis, but its role in non-functioning pituitary neuroendocrine tumors (NF-PitNETs) remains unclear. This study aimed to elucidate ...

The approval was based on the results of the phase 3 CABINET study, which compared cabozantinib to a placebo in patients with advanced pancreatic neuroendocrine tumors and advanced extrapancreatic ...

MONDAY, March 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated ...

MONDAY, March 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced ...